Ulcerative Colitis Market braces for growth-injected business opportunities with the lion’s share of revenues coming from North America

Ulcerative Colitis is an inflammatory bowel disease that causes ulcers and is extremely painful. It has been diagnosed more than twice as many women as men, with one in seven women having it at some point during their lives. Ulcerative Colitis affects about one percent of the population.

Although not well understood, it is believed to be due to a problem with the immune system, but the exact cause is still unknown. The immune system normally responds to infections by producing white blood cells to attack the source of the infection, but in Ulcerative Colitis the white blood cells fail to reach the site of inflammation, so they help to bring about the symptoms. In July 2021, Eli Lilly and Company revealed the results of its Phase II clinical study concluding that variations in gene expression of ulcerative colitis patients over a three-month treatment were neutral for one year.

LIMITED TIME OFFER – Hurry Up!

Exclusive offer!!! Purchase the report at a discounted rate!!!

Get Discount for Buyers USD 2000 OFF On Any Research Report
Buy Now and Get Instant Discount: https://www.coherentmarketinsights.com/promo/buynow/238

Ulcerative colitis market taxonomy:
Global Market by Drug Type
Infliximab
Golimumab
Adalimumab
Vedolizumab
Mesalamine
Budesonide
Balsazide

Global Market by Dosage Form
Parenteral
Oral

Company Coverage: -
- AbbVie Inc.
- Bausch Health Companies Inc. (Salix Pharmaceutical)
- Boehringer Ingelheim GmbH
- Johnson and Johnson
- Merck and Co.
- Novartis AG
- Shire
- Takeda Pharmaceuticals
- Teva Pharmaceuticals Ltd
- Pfizer Inc.

The ulcerative colitis market is projected to be driven by the rising participation of major companies in product development linked to the field. Besides, increasing accessibility and decreasing costs of biosimilars in the emerging economies is creating positive prospects for the ulcerative colitis market. On the contrary, the expiration of medication patents and strict government rules governing biosimilar licensing can act as a potential barrier in the growth of the ulcerative colitis market.

Ulcerative Colitis has a high risk for those with AIDS and HIV/AIDS, and those who smoke, have a family history, are overweight or obese, have a poor diet and physical activity. Other potential risk factors include chronic liver disease, diabetes, asthma, multiple sclerosis, and steroid use. In July 2021, Rinvoq, a Janus kinase (JAK) inhibitor developed by AbbVie Pharmaceuticals, was found to be a potential treatment options for individuals suffering from ulcerative colitis (UC). Ulcerative Colitis is also more common in women than in men, and accounts for approximately half of all cases of Crohn's Disease. Ulcerative Colitis has a higher incidence in people who live in areas that experience high levels of air pollution, with those living in townships, urban settlements and beaches suffering the most from this disease.

In the territorial breakdown, the ulcerative colitis market in the North American region is foreseen to augment at a significant rate owing to the growing incidences of ulcerative colitis coupled with the rising research and development efforts by major participants for treatment of this condition. In parallel, the Asia Pacific region is also sustaining well for the ulcerative colitis market on the heels of rising expenditure on the healthcare sector along with the growing ulcerative colitis patient caseload.

For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/ulcerative-colitis-market-238

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle,
WA 98154, U.S.
Phone:
US: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

About Us:
Coherent Market Insights (CMI) is a global market intelligence and consulting organization focused on assisting plethora of clients achieve transformational growth by helping them make critical business decisions. The company is headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. The company’s client base includes players from across various business verticals in over 47 countries globally. It takes pride in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and start-ups looking to establish a foothold in the market.

This release was published on openPR.